Keros Therapeutics KROS
NASDAQ KROS
$11.35 +0.17 (+1.52%)
At close: Oct 22, 2026 · 4:00 PM EDT

Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)

Updated

Keros Therapeutics' Depreciation & Amortization (CF) was $400,000 in Q4 2025, up 20.5% from $332,000 a year earlier and up 1.3% from the prior quarter.

Analysis

Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends

For FY2025, Depreciation & Amortization (CF) at Keros Therapeutics came in at $1.51 million, up 22.8% from FY2024.

  • Depreciation & Amortization (CF) has now increased for six consecutive years, with a five-year compound annual growth rate of 40.3% (FY2020 to FY2025).
  • In earlier years, Depreciation & Amortization (CF) was $1.23 million in FY2024 (+50.8%), $815,000 in FY2023 (+20.9%), $674,000 in FY2022 (+78.3%) and $378,000 in FY2021 (+36.0%).
  • The Q4 2025 figure marks the highest quarterly Depreciation & Amortization (CF) in data going back to Q1 2019.
  • Compared with a year earlier, Depreciation & Amortization (CF) has increased for ten straight quarters, with growth averaging 37.7% over the last eight quarters.
  • The best year-over-year quarter for Depreciation & Amortization (CF) over five years was Q2 2022 (growth of 238.5%); the worst was Q2 2023 (a decline of 38.0%).
  • Per Business Quant data, KROS's Depreciation & Amortization (CF) in the three quarters before Q4 2025 was $395,000 (Q3 2025), $370,000 (Q2 2025) and $344,000 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 2.12 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 194.00 Mn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 1.93 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 98.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 1.62 Bn
10 Keros Therapeutics 224.56 Mn -1.70 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 400,000.00
Sep 30, 2025 395,000.00
Jun 30, 2025 370,000.00
Mar 31, 2025 344,000.00
Dec 31, 2024 332,000.00
Sep 30, 2024 314,000.00
Jun 30, 2024 306,000.00
Mar 31, 2024 277,000.00
Dec 31, 2023 247,000.00
Sep 30, 2023 210,000.00
Jun 30, 2023 191,000.00
Mar 31, 2023 167,000.00
Dec 31, 2022 127,000.00
Sep 30, 2022 126,000.00
Jun 30, 2022 308,000.00
Mar 31, 2022 113,000.00
Dec 31, 2021 104,000.00
Sep 30, 2021 103,000.00
Jun 30, 2021 91,000.00
Mar 31, 2021 80,000.00
API Access

Keros Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=KROS&period=max&api_key=YOUR_API_KEY